Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi-Aventis Sees India's Shantha As Global Hub For Its Biotech Plans

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - French drug maker Sanofi-Aventis sees Shantha Biotech - its latest Indian acquisition - as a hub to further its global biotech ambitions but may not rush to buy more companies in India

You may also be interested in...



From Allstar to Insuman, Sanofi Expands ‘Make In India’ Plans

The French drug firm Sanofi is bullish on producing some of its products in India. It first acquired Shantha Biotechnics and it manufacturing capabilities in 2009 and later started making its pen devices locally, and is now setting up a large project to make the human insulin product Insuman.

Deals Of The Week: NewDrugs4BadBugs Initiative, GSK/Auxilium, DaVita/Healthcare Partners

WHO Does What It Warned: Delists Shantha Biotech's Pentavalent Vaccine Shan5; More Pains For Sanofi-Aventis?

MUMBAI - In a move that could in the short term severely impair the reputation of Hyderabad-based vaccines maker Shantha Biotechnics, now part of Sanofi-Aventis, the World Health Organization has delisted its popular pentavalent vaccine Shan5, which is used by scores of nations as part of their national immunization programs for the prevention against deadly diseases like diphtheria, tetanus, hepatitis B and Hib

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC072612

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel